{"id":"edaravone-dexborneol-sublingual-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash or allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edaravone works by neutralizing hydroxyl radicals and other reactive oxygen species that accumulate during acute ischemic stroke, thereby limiting neuronal damage and apoptosis. Dexborneol, a natural monoterpene alcohol, acts as a permeation enhancer that improves the sublingual absorption of edaravone, allowing for faster systemic delivery and potentially improved clinical efficacy compared to intravenous administration.","oneSentence":"Edaravone is a free radical scavenger that reduces oxidative stress and neuroinflammation, while dexborneol enhances absorption and bioavailability through sublingual delivery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:33.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT07454473","phase":"PHASE4","title":"Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study","status":"RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-02","conditions":"Chemo Brain","enrollment":80},{"nctId":"NCT06674460","phase":"PHASE3","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08-01","conditions":"Cerebral Small Vessel Disease, Ischemic Stroke","enrollment":600},{"nctId":"NCT06315231","phase":"PHASE2","title":"Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-04-08","conditions":"Post-stroke Cognitive Impairment","enrollment":226},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Edaravone Dexborneol Sublingual Tablets","genericName":"Edaravone Dexborneol Sublingual Tablets","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edaravone is a free radical scavenger that reduces oxidative stress and neuroinflammation, while dexborneol enhances absorption and bioavailability through sublingual delivery. Used for Acute ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}